HHS awards $107M contract to Venatorx Pharmaceuticals for biotechnology R&D, with a significant portion allocated to cost-sharing

Contract Overview

Contract Amount: $107,189,039 ($107.2M)

Contractor: Venatorx Pharmaceuticals Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2019-07-17

End Date: 2025-09-30

Contract Duration: 2,267 days

Daily Burn Rate: $47.3K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: COST SHARING

Sector: R&D

Official Description: VENATORX PHARMACEUTICALS, INC.

Place of Performance

Location: DOWNINGTOWN, CHESTER County, PENNSYLVANIA, 19335

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $107.2 million to VENATORX PHARMACEUTICALS INC for work described as: VENATORX PHARMACEUTICALS, INC. Key points: 1. The contract's cost-sharing component suggests a partnership approach, potentially mitigating government financial risk while incentivizing contractor performance. 2. While the contract is for R&D, the 'definitive contract' type indicates a long-term commitment, requiring careful monitoring of milestones and deliverables. 3. The specific NAICS code (541714) points to a focus on biotechnology research, a critical area for public health preparedness. 4. The contract duration of 2267 days (over 6 years) necessitates a long-term view of the research outcomes and their potential impact. 5. The absence of small business set-aside flags indicates this contract was not specifically targeted for small business participation. 6. The contract's value, while substantial, needs to be benchmarked against similar R&D investments in the biotechnology sector to assess value for money.

Value Assessment

Rating: fair

Benchmarking the value of this R&D contract is challenging without specific details on the research scope and expected outcomes. The cost-sharing arrangement implies a shared investment, which can be a positive indicator of commitment from both parties. However, the ultimate value for money will depend on the successful development of the research objectives. Comparing this to other biotechnology R&D contracts would require access to detailed project specifics and funding levels for similar initiatives.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting that multiple vendors had the opportunity to bid. This process is generally favorable for price discovery and ensuring a competitive market. The fact that it was competed openly implies that Venatorx Pharmaceuticals was selected based on merit and competitive pricing among potential bidders.

Taxpayer Impact: Full and open competition typically benefits taxpayers by driving down costs through market forces and ensuring the government receives the best value available.

Public Impact

The primary beneficiaries are likely the public, through advancements in biotechnology that could enhance public health preparedness. The contract supports research and development in biotechnology, potentially leading to new medical countermeasures or diagnostic tools. The geographic impact is primarily centered in Pennsylvania, where Venatorx Pharmaceuticals is located, potentially creating or sustaining high-skilled jobs in the region. The contract's focus on R&D in biotechnology will likely impact the scientific workforce, fostering innovation and expertise in this specialized field.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

The long-term nature of the R&D contract requires sustained oversight to ensure progress and prevent scope creep.
The cost-sharing aspect, while potentially beneficial, needs careful tracking to ensure equitable distribution of costs and benefits.
Assessing the true value of R&D outcomes can be difficult and may take years, making performance evaluation a long-term challenge.

Positive Signals

Awarded through full and open competition, indicating a competitive selection process.
The cost-sharing model demonstrates a commitment from the contractor, aligning incentives with the government's objectives.
The contract supports a critical area of R&D in biotechnology, aligning with national health security priorities.

Sector Analysis

This contract falls within the biotechnology research and development sector, a rapidly growing and highly specialized area within the broader healthcare and life sciences industry. The market for biotechnology R&D is characterized by significant investment, long development cycles, and high potential for innovation. Government funding plays a crucial role in advancing cutting-edge research that may not be immediately commercially viable. Comparable spending benchmarks would involve looking at other federal investments in similar biotechnology R&D initiatives, particularly those focused on public health preparedness.

Small Business Impact

This contract does not appear to have a small business set-aside. While the primary award is to Venatorx Pharmaceuticals, Inc., the contract terms do not explicitly mandate subcontracting to small businesses. The impact on the small business ecosystem would depend on whether Venatorx chooses to engage small businesses as subcontractors for specific services or supplies related to the R&D activities.

Oversight & Accountability

Oversight for this contract would likely be managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS. Accountability measures would be tied to the research milestones and deliverables outlined in the definitive contract. Transparency is generally maintained through contract award databases, though specific research progress details may be proprietary. The Inspector General's office for HHS would have jurisdiction to investigate any potential fraud, waste, or abuse related to this funding.

Related Government Programs

Biotechnology Research Programs
Public Health Preparedness Initiatives
National Institutes of Health (NIH) Grants
Department of Defense (DoD) R&D Contracts
Advanced Research Projects Agency for Health (ARPA-H)

Risk Flags

Long-term R&D project risk
Potential for research failure
Difficulty in benchmarking R&D value
Need for sustained oversight

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $107.2 million to VENATORX PHARMACEUTICALS INC. VENATORX PHARMACEUTICALS, INC.

Who is the contractor on this award?

The obligated recipient is VENATORX PHARMACEUTICALS INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $107.2 million.

What is the period of performance?

Start: 2019-07-17. End: 2025-09-30.

What is the specific research objective of this contract and what are the key performance indicators (KPIs) for Venatorx Pharmaceuticals?

The provided data does not specify the exact research objective or the key performance indicators (KPIs) for this contract. However, given the agency (ASPR) and the NAICS code (541714 - Research and Development in Biotechnology), the objective likely relates to developing novel biotechnological solutions for public health threats, such as infectious diseases or chemical/biological agents. KPIs would typically include achieving specific research milestones, demonstrating proof-of-concept for new technologies, or developing prototypes within defined timelines and budgets. The cost-sharing aspect suggests that Venatorx has a vested interest in achieving these objectives, as their own investment is on the line. Further details would be found in the contract's statement of work.

How does the $107 million award compare to typical R&D spending for similar biotechnology projects within HHS or other federal agencies?

The $107 million award is a substantial investment, reflecting the high costs associated with cutting-edge biotechnology research and development. To benchmark this against similar contracts, one would need to analyze historical data for R&D contracts awarded by agencies like ASPR, NIH, or BARDA (Biomedical Advanced Research and Development Authority) for projects with comparable scope and duration. R&D in biotechnology can range from tens of millions to hundreds of millions of dollars, depending on the stage of development (e.g., basic research vs. clinical trials), the complexity of the technology, and the potential market or public health impact. Without specific details on the project's phase and goals, a precise comparison is difficult, but the amount suggests a significant, multi-year research effort.

What are the potential risks associated with a long-term (2267 days) definitive contract for biotechnology R&D, and how are they mitigated?

Long-term R&D contracts carry inherent risks, including the possibility of research failure, technological obsolescence, changing scientific landscapes, and cost overruns. For biotechnology, the risk of failure to achieve desired scientific outcomes is particularly high due to the experimental nature of the work. Mitigation strategies often include phased funding tied to achievable milestones, rigorous technical reviews, flexible contract modifications to adapt to new findings, and strong project management oversight. The cost-sharing arrangement in this contract also serves as a risk mitigation tool, as it requires the contractor to bear a portion of the financial burden, incentivizing efficient and successful research. Clear performance metrics and regular reporting are crucial for managing these risks.

What is Venatorx Pharmaceuticals' track record with federal R&D contracts, particularly with HHS or ASPR?

Information regarding Venatorx Pharmaceuticals' specific track record with federal R&D contracts, especially with HHS or ASPR, is not detailed in the provided data. A comprehensive assessment would require reviewing federal procurement databases (like SAM.gov or FPDS) for past awards, performance evaluations (e.g., Contractor Performance Assessment Reporting System - CPARS), and any history of contract modifications, disputes, or terminations. Understanding their past performance in delivering on R&D objectives, managing budgets, and adhering to timelines would provide crucial context for evaluating the current contract's risk profile and likelihood of success.

How does the 'Cost Sharing' (PT: COST SHARING) aspect of this contract influence the financial risk and potential reward for both the government and Venatorx Pharmaceuticals?

The 'Cost Sharing' designation indicates that Venatorx Pharmaceuticals is contributing a portion of the project's costs, rather than the government funding 100% of the effort. This arrangement significantly influences the financial dynamics. For the government, it reduces the upfront financial exposure and risk, as the contractor shares in the investment. It also serves as a strong indicator of the contractor's confidence in the project's potential success and their commitment to achieving the research objectives. For Venatorx Pharmaceuticals, it represents a higher potential reward if the research is successful, as they will have invested their own resources to achieve a valuable outcome. Conversely, it also means they bear a greater financial risk if the research fails or encounters significant setbacks. This shared risk/reward model is often employed in R&D to foster greater accountability and efficiency.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: BAA18100SOL00003

Offers Received: 1

Pricing Type: COST SHARING (T)

Evaluated Preference: NONE

Contractor Details

Address: 30 SPRING MILL DR, MALVERN, PA, 19355

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $147,481,537

Exercised Options: $132,372,213

Current Obligation: $107,189,039

Actual Outlays: $36,719,709

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline